Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Short-term Investments (2020 - 2025)

RxSight's Short-term Investments history spans 6 years, with the latest figure at $208.2 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 5.6% year-over-year to $208.2 million; the TTM value through Dec 2025 reached $208.2 million, down 5.6%, while the annual FY2025 figure was $208.2 million, 5.6% down from the prior year.
  • Short-term Investments reached $208.2 million in Q4 2025 per RXST's latest filing, up from $197.9 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $220.5 million in Q4 2024 to a low of $20.0 million in Q2 2021.
  • Average Short-term Investments over 5 years is $143.9 million, with a median of $135.0 million recorded in 2021.
  • Peak YoY movement for Short-term Investments: skyrocketed 423.13% in 2022, then tumbled 35.14% in 2024.
  • A 5-year view of Short-term Investments shows it stood at $135.0 million in 2021, then tumbled by 30.38% to $94.0 million in 2022, then increased by 25.03% to $117.5 million in 2023, then soared by 87.69% to $220.5 million in 2024, then dropped by 5.6% to $208.2 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Short-term Investments are $208.2 million (Q4 2025), $197.9 million (Q3 2025), and $187.1 million (Q2 2025).